VistaGen Therapeutics, Inc. — Form 10-Q Summary
Business context and reporting period. This quarterly report covers the quarter and nine months ended December 31, 2015, in the company’s fiscal year ending March 31, 2016. VistaGen is a clinical-stage biopharmaceutical company with no product revenue. Its lead candidate, AV-101, entered a Phase 2A study for treatment-resistant major depressive disorder (MDD) in late 2015; the National Institute of Mental Health (NIMH) is conducting and funding the study under a cooperative agreement. The company also pursues stem-cell-based drug rescue and exploratory regenerative medicine programs.
Financial results and liquidity
| Metric | Three months ended Dec. 31, 2015 | Nine months ended Dec. 31, 2015 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $0.81 million | $2.84 million |
| General and administrative expense | $1.34 million | $6.51 million |
| Operating loss | $2.14 million | $9.35 million |
| Net loss | $2.15 million | $38.72 million |
| Net loss attributable to common stockholders | $3.45 million | $41.99 million |
| Basic loss per common share | $1.95 | $25.45 |
The company reported no revenue or gross margin. Nine-month operating cash use was $3.50 million, investing cash use was $0.005 million, and financing provided $4.59 million. Cash increased from $70,000 at March 31 to $1.16 million at December 31, 2015.
At December 31, 2015, current assets were $1.89 million and current liabilities were $2.10 million. Total assets were $2.01 million, total liabilities were $3.61 million, and stockholders’ deficit was $1.60 million. The balance sheet reported $73,800 of current notes payable and accrued interest, $29,300 of non-current notes payable, and $1,100 of current capital lease obligations. Most former borrowings were converted into preferred equity.
Changes versus the prior comparable period
- Quarterly net loss rose from $1.09 million in 2014 to $2.15 million in 2015; quarterly operating expenses increased from $1.12 million to $2.14 million. R&D increased from $445,400 to $806,300, and G&A from $671,300 to $1.34 million.
- Nine-month net loss increased from $7.66 million to $38.72 million. The principal unusual driver was a $26.70 million non-cash loss on extinguishment of debt, associated with converting approximately $17.2 million of debt and related amounts into Series B preferred stock and warrants.
- Nine-month R&D and G&A increased to $2.84 million and $6.51 million, respectively. Management cited higher patent and technology costs, professional services, and non-cash stock compensation and warrant-modification expense. Nine-month stock-based compensation was $3.87 million.
- Nine-month interest expense declined to $769,800 from $2.18 million, primarily because debt was converted and interest accruals and discount amortization largely ceased. A $1.89 million non-cash warrant-liability charge was recorded before that liability was eliminated following warrant amendments.
- Financing cash provided increased to $4.59 million from $1.89 million in the prior period, including $4.40 million of proceeds from Series B unit sales. Cash at period-end was $1.16 million versus $13,200 a year earlier.
Outlook, management commentary, and risks
- Management stated that December 31 cash was insufficient to fund planned operations for the next 12 months, with expected cash expenditures of approximately $6.0 million. Additional financing is required; the company warned that it may need to reduce, defer, or discontinue research and development, and may be unable to continue as a going concern if financing is not obtained.
- The company expects continuing losses and negative operating cash flows and has no current revenue-generating arrangements. The NIMH-funded Phase 2A MDD study was expected to enroll 24–28 patients; the filing provides no clinical results or firm completion timetable.
- VistaGen intends to seek additional capital through securities issuances, collaborations, licensing, and grants, while managing operating costs. Financing may be unavailable or dilutive, or may require unfavorable terms or surrender of rights. The August 2015 agreement with Platinum was partially funded; Platinum cancelled its remaining $1.35 million purchase right in December.
- Series B preferred stock accrues a 10% annual in-kind dividend and is convertible into common stock, subject to conditions. The filing reported $1.42 million of accrued-dividend liability and approximately $26.54 million of Series B liquidation value at December 31, 2015. Unit sales also generated deemed dividends that increased loss attributable to common stockholders.
- Subsequent events through February 12, 2016 included $128,000 of additional Series B unit sales; creation of Series C preferred; exchanges of Platinum-related warrants and shares for Series C; and exchanges of other warrants for common shares. These transactions affect dilution and the capital structure.
- Key business risks include clinical or regulatory failure or delay, dependence on the NIMH and other third parties, reliance on contract manufacturers, competition, intellectual-property uncertainty, and limited access to capital. The filing reported no legal proceedings and stated that disclosure controls were effective, with no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Current cash runway and the status, amount, timing, and terms of additional financing after February 12, 2016.
- Progress, enrollment, safety, and results of the NIMH-funded AV-101 Phase 2A study; no study results are reported here.
- The composition and potential dilution of common and preferred shares, accrued Series B dividends, outstanding warrants, and subsequent warrant and preferred-stock exchanges.
- The assumptions and accounting treatment behind the $26.70 million debt-extinguishment loss and other substantial non-cash compensation and warrant charges.
- The company’s ability to continue as a going concern, given $1.16 million of cash against stated expected cash expenditures of approximately $6.0 million over 12 months.